Uterine body mixed cancer

Summary

Uterine body mixed cancer (MONDO:0002879) is a cancer and 1 clinical trial. Top therapeutic interventions include nintedanib. A subtype of malignant mixed neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine body mixed cancer
Mondo ID	MONDO:0002879
DOID	DOID:4114
NCIT	C6311
UMLS	C1334628
MedGen	233163
GARD	0023285
Anatomy (UBERON)	UBERON:0009853
Is cancer (heuristic)	yes

Also known as: malignant body of uterus mixed neoplasm · malignant body of uterus mixed tumor · malignant body of uterus mixed tumour · malignant corpus uteri mixed neoplasm · malignant corpus uteri mixed tumor · malignant corpus uteri mixed tumour · malignant mixed neoplasm of body of uterus · malignant mixed neoplasm of corpus uteri · malignant mixed neoplasm of the body of uterus · malignant mixed neoplasm of the corpus uteri · malignant mixed neoplasm of the uterine body · malignant mixed neoplasm of the uterine corpus · malignant mixed neoplasm of uterine body · malignant mixed neoplasm of uterine corpus · malignant mixed tumor of body of uterus · malignant mixed tumor of corpus uteri · malignant mixed tumor of the body of uterus · malignant mixed tumor of the corpus uteri · malignant mixed tumor of the uterine body · malignant mixed tumor of the uterine corpus (+16 more)

Disease family

This is a subtype of malignant mixed neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mixed neoplasm › uterine body mixed cancer

Related subtypes (14): carcinoma ex pleomorphic adenoma, carcinosarcoma, adenocarcinofibroma, ovarian seromucinous carcinoma, adenosarcoma, Wilms tumor, combined lung carcinoma, mixed lobular and ductal breast carcinoma, gonadoblastoma, anaplastic oligoastrocytoma, malignant mixed epithelial stromal tumor of the kidney, malignant phyllodes tumor, malignant vaginal mixed epithelial and mesenchymal neoplasm, adenoacanthoma

Subtypes (4): uterine corpus adenosarcoma, uterine corpus adenocarcinofibroma, uterine corpus carcinofibroma, carcinosarcoma of the corpus uteri

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01225887	PHASE2	COMPLETED	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NINTEDANIB	4	1